The past year was an exciting time for clinical lipidology when we learnt more about existing therapies as well as therapies targeting novel pathways discovered through genetic studies. LDL cholesterol remained the main target and a variety of drugs to lower LDL cholesterol through different mechanisms were explored. Emerging evidence on the atherogenity of triglyceride-rich lipoproteins led to renewed interest in lowering them with new treatments. Lp(a) was back in focus with evidence on causality and new targeted therapeutics which dramatically lower Lp(a) levels. We will be able to personalise lipid lowering therapy further with this enriched armamentarium once we have the results of the cardiovascular outcome studies with some of these new agents.

The year in cardiovascular medicine 2021: dyslipidaemia / L. Tokgozoglu, C. Orringer, H.N. Ginsberg, A.L. Catapano. - In: EUROPEAN HEART JOURNAL. - ISSN 0195-668X. - 43:8(2022 Feb 21), pp. 807-817. [10.1093/eurheartj/ehab875]

The year in cardiovascular medicine 2021: dyslipidaemia

A.L. Catapano
Ultimo
2022

Abstract

The past year was an exciting time for clinical lipidology when we learnt more about existing therapies as well as therapies targeting novel pathways discovered through genetic studies. LDL cholesterol remained the main target and a variety of drugs to lower LDL cholesterol through different mechanisms were explored. Emerging evidence on the atherogenity of triglyceride-rich lipoproteins led to renewed interest in lowering them with new treatments. Lp(a) was back in focus with evidence on causality and new targeted therapeutics which dramatically lower Lp(a) levels. We will be able to personalise lipid lowering therapy further with this enriched armamentarium once we have the results of the cardiovascular outcome studies with some of these new agents.
Antisense; CRISPR; Cardiovascular diseases; LDL-C. Triglycerides; Lipids; Lp(a); Nucleic acid therapeutics; PCSK9 inhibitors; RNA interference; Statins;
Settore BIO/14 - Farmacologia
21-feb-2022
3-feb-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
ehab875.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.04 MB
Formato Adobe PDF
1.04 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/913108
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact